Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hangzhou Tigermed Consulting Co (HKSE:03347) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Hangzhou Tigermed Consulting Co Piotroski F-Score Related Terms
Hangzhou Tigermed Consulting Co Piotroski F-Score Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hangzhou Tigermed Consulting Co Piotroski F-Score Chart
HKSE:03347 vs TMO, DHR, NTRA: Piotroski F-Score Comparison
For the Diagnostics & Research subindustry, Hangzhou Tigermed Consulting Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hangzhou Tigermed Consulting Co Piotroski F-Score vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Hangzhou Tigermed Consulting Co's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Hangzhou Tigermed Consulting Co's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This Year (Jun26) TTM:
Last Year (Jun25) TTM:
Net Income was 696.232 + -146.425 + 55.694 + -534.639 = HK$71 Mil. Cash Flow from Operations was 361.657 + 418.168 + 360.791 + 125.017 = HK$1,266 Mil. Revenue was 1940.218 + 1996.163 + 2045.788 + 2204.807 = HK$8,187 Mil. Gross Profit was 532.9 + 450.262 + 544.976 + 625.349 = HK$2,153 Mil.
Average Total Assets from the begining of this year (Jun25)
to the end of this year (Jun26) was
(31157.27 + 31455.993 + 31328.673 + 32706.379 + 32264.601) / 5 = HK$31782.5832 Mil. Total Assets at the begining of this year (Jun25) was HK$31,157 Mil. Long-Term Debt & Capital Lease Obligation was HK$2,237 Mil. Total Current Assets was HK$7,644 Mil. Total Current Liabilities was HK$3,075 Mil.
Net Income was 352.973 + -435.914 + 177.418 + 238.143 = HK$333 Mil.
Revenue was 1882.096 + 1639.416 + 1677.097 + 1843.226 = HK$7,042 Mil. Gross Profit was 701.624 + 290.12 + 503.684 + 555.512 = HK$2,051 Mil.
Average Total Assets from the begining of last year (Jun24)
to the end of last year (Jun25) was
(32745.348 + 33335.914 + 30611.243 + 30804.268 + 31157.27) / 5 = HK$31730.8086 Mil. Total Assets at the begining of last year (Jun24) was HK$32,745 Mil. Long-Term Debt & Capital Lease Obligation was HK$1,030 Mil. Total Current Assets was HK$6,784 Mil. Total Current Liabilities was HK$3,712 Mil.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Hangzhou Tigermed Consulting Co's current Net Income (TTM) was 71.
==> Positive ==> Score 1.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Hangzhou Tigermed Consulting Co's current Cash Flow from Operations (TTM) was 1,266.
==> Positive ==> Score 1.
Question 3. Change in Return on Assets
Compare this year's return on assets (1) to last year's return on assets.
Hangzhou Tigermed Consulting Co's return on assets of this year was 0.00227433. Hangzhou Tigermed Consulting Co's return on assets of last year was 0.01015778.
==> Last year is higher ==> Score 0.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Hangzhou Tigermed Consulting Co's gearing of this year was 0.07037757. Hangzhou Tigermed Consulting Co's gearing of last year was 0.03244714.
==> Last year is lower than this year ==> Score 0.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Hangzhou Tigermed Consulting Co's current ratio of this year was 2.48550979. Hangzhou Tigermed Consulting Co's current ratio of last year was 1.82774711.
==> This year's current ratio is higher. ==> Score 1.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Hangzhou Tigermed Consulting Co's number of shares in issue this year was 904.113. Hangzhou Tigermed Consulting Co's number of shares in issue last year was 832.832.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Hangzhou Tigermed Consulting Co's gross margin of this year was 0.26303815. Hangzhou Tigermed Consulting Co's gross margin of last year was 0.29125079.
==> Last year's gross margin is higher ==> Score 0.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Hangzhou Tigermed Consulting Co's asset turnover of this year was 0.26276294. Hangzhou Tigermed Consulting Co's asset turnover of last year was 0.21504841.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
1
+
1
+
0
+
1
+
0
+
1
+
0
+
0
+
1
=
5
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Hangzhou Tigermed Consulting Co has an F-score of 5 indicating the company's financial situation is typical for a stable company.
Hangzhou Tigermed Consulting Co (HKSE:03347) has a Piotroski F-Score of 5 as of Sep. 12, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Hangzhou Tigermed Consulting Co and its competitors. This is near median its historical median of 5.00. Over the past decade, Hangzhou Tigermed Consulting Co's Piotroski F-Score has ranged from 2.00 to 7.00. According to the industry distribution chart, Hangzhou Tigermed Consulting Co ranks #71 out of 208 companies in the Medical Diagnostics & Research industry, placing it in the top 34.1%.
Is Hangzhou Tigermed Consulting Co's Piotroski F-Score too high?
Hangzhou Tigermed Consulting Co's current Piotroski F-Score of 5 is near median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 7.00. The Medical Diagnostics & Research industry median Piotroski F-Score is 5.00. Hangzhou Tigermed Consulting Co's value of 5 is 0% at this industry median. Based on the distribution chart, Hangzhou Tigermed Consulting Co ranks #71 out of 208 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Hangzhou Tigermed Consulting Co has a GF Score™ of 92/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Hangzhou Tigermed Consulting Co's Piotroski F-Score compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Hangzhou Tigermed Consulting Co ranks #71 out of 208 companies for Piotroski F-Score. This puts Hangzhou Tigermed Consulting Co in the upper half of its industry. The industry median Piotroski F-Score is 5.00. Hangzhou Tigermed Consulting Co's value of 5 is 0% at this benchmark. Historically, Hangzhou Tigermed Consulting Co's own Piotroski F-Score has ranged from 2.00 to 7.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 5.00, Hangzhou Tigermed Consulting Co has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Diagnostics & Research company?
The median Piotroski F-Score among Medical Diagnostics & Research companies is 5.00, based on 208 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hangzhou Tigermed Consulting Co's current Piotroski F-Score of 5 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Hangzhou Tigermed Consulting Co and its competitors. For the Medical Diagnostics & Research industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hangzhou Tigermed Consulting Co's current Piotroski F-Score is 5, which is near median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hangzhou Tigermed Consulting Co stock overvalued right now?
Based on GuruFocus' analysis, Hangzhou Tigermed Consulting Co (HKSE:03347) is currently considered Fairly Valued. The stock's GF Value™ is HK$45.33, compared to a current price of HK$41.40 — trading 8.7% below its estimated fair value. The current Piotroski F-Score is 5, which is near median its 10-year median of 5.00 and 0% at the Medical Diagnostics & Research industry median of 5.00. Hangzhou Tigermed Consulting Co's overall GF Score™ is 92/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Hangzhou Tigermed Consulting Co (HKSE:03347), the current Piotroski F-Score is 5 as of Sep. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hangzhou Tigermed Consulting Co (HKSE:03347) Overvalued in 2026?
Based on GuruFocus' analysis, Hangzhou Tigermed Consulting Co stock appears to be undervalued.
The current stock price of HK$41.40 is trading 8.7% below its estimated GF Value™ of HK$45.33.
GuruFocus considers Hangzhou Tigermed Consulting Co to be Fairly Valued.
Key valuation signals for HKSE:03347:
Piotroski F-Score: 5 (near median its 10-year median of 5.00)
GF Value™: HK$45.33 vs. price of HK$41.40 (8.7% below fair value)
Industry Position: 0% at the Medical Diagnostics & Research median (#71 of 208)
No single metric tells the full story. See the HKSE:03347 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hangzhou Tigermed Consulting Co Ltd is a China-based provider of comprehensive biopharmaceutical R&D services, with an expanding world-wide presence. The Group is principally engaged in CRO services.
92GF Score
Get the complete analysis for HKSE:03347
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:03347 has been successfully added to your 
